Info

Target Discovery's next generation clinical diagnostics utilize new technologies to uniquely discriminate the specific isoform modifications of protein biomarkers. These Isonostics products transform the effectiveness of disease diagnosis, patient profiling in clinical trials, and therapy optimization, bringing "Personalized Medicine" from concept to reality. TDI's internal programs focus on the development of isoform-specific cancer diagnostics. Through collaborative partnerships, we also customize the application of our discovery and clinical platforms to other disease areas and broader challenges in life sciences R&D. Isoform diagnostics are enabled through TDI's unique immuno-affinity capillary electrophoresis technology. While developing initial diagnostics based upon known isoform biomarkers, TDI's patented "mass defect" and stable isotope technologies provide a unique discovery engine that reaches beyond current boundaries to identify and validate new biomarkers for an expanding pipeline of isoform diagnostics. Our technology innovations are forging missing links in the evolutionary pathway "From Omics To Knowmics," using hypothesis-driven science to advance biological discovery and understanding, and ultimately to contribute to improved healthcare and quality of life.